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Abstract: Malaria, a disease of poverty and high morbidity and mortality in the tropical world, 
has led to a worldwide search for control measures. To that end, good antimalarial chemothera-
pies have been difficult to find in the global market and those that seem to be most effective are 
rapidly becoming ineffective due to the emergence and spread of drug resistance. Artemisinin, a 
very effective yet expensive antimalarial, has quickly become the recommended drug of choice 
when all other possibilities fail. However, for all its promise as the next great antimalarial, the 
outlook is bleak. Resistance is developing to artemisinin while another effective antimalarial is 
not in sight. Malaria endemic areas which are mostly in developing countries must deal with the 
multifaceted process of changing and implementing new national malaria treatment guidelines. 
This requires complex interactions between several sectors of the affected society which in 
some cases take place within the context of political instability. Moreover, the cost associated 
with preventing and containing the spread of antimalarial resistance is detrimental to economic 
progress. This review addresses the impact of artemisinin resistance on the socioeconomic 
structure of malaria endemic countries.
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Malaria, a mosquito-borne parasitic disease, affects 510 million people causing 
almost 3 million deaths annually.1 For more than 50 years, cinchona alkaloids and 
their   derivatives were an integral part of malaria control. Indeed, chloroquine was 
one of the most effective synthetic antimalarial drugs ever produced. However, 
chloroquine-resistance falciparum malaria was first reported in South East Asia and 
South America and has now spread through Asia, Africa, and South America.2 This 
has led to a global resurgence of malaria. Currently, these alkaloids are being replaced 
by the terpene Artemisia annua, also known as qing hao or sweetworm, whose active 
ingredient is artemisinin. Discovered in 1971 by Chinese scientists, artemisinin was 
introduced to the world in 1979.3 Although quite expensive to produce, artemisinin 
is one of the most effective antimalarials. It is currently grown by farmers in China, 
Vietnam, and parts of Africa. With a long growing season, the process of extracting 
artemisinin from the leaves is complex and time consuming. Because of the difficulty 
in extracting it from the plant, a semi-synthetic version generated by the addition 
of chemical groups to extracted artemisinin is commonly used. Dihydroartemisinin 
(DHA) is the product of the first step; additional synthetic steps give rise to artesunate, 
artemether, and arteether which are metabolized back to dihydroartemisinin in the 
body (Figure 1). The artemisinin derivatives possess greater antimalarial properties. 
They are active against multiple drug-resistant parasites and have a very low level Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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Malaria drug resistance
The reemergence of malaria drug resistance is a major 
  problem in the tropical and subtropical world. Several factors 
influence the reemergence of drug resistance. Among them 
is the level of immunity against the malaria parasite in the 
population.9 For instance, in low or unstable transmission 
areas, drug resistance propagates rapidly. This is due to mini-
mal immunity in a population, thus parasite infections lead 
to acute symptomatic disease which is most likely treated. 
Therefore, drug resistance is likely to propagate rapidly due 
to high drug pressure on existing parasites. In fact, certain 
  mutations are prevalent as a result of high drug pressure in 
most sub-Saharan countries.10 On the other hand, in areas 
where malaria transmission is high, the spread of drug resis-
tance is restricted because of high levels of immunity. Here, 
there is less need for treatment in a population because there 
are fewer clinical symptoms. One study based in Tanzania 
showed that immunity enhanced drug efficacy.10
Changing national malaria 
treatment policy
Malaria parasite resistance is a complex process that requires 
constant monitoring and strategic actions to save lives. 
New national malaria treatment policies have been slow 
to implement at the country level and therefore have not 
been very effective in relieving the burden of disease. Many 
malaria endemic countries have relied on chloroquine as a 
first-line of treatment against malaria for several decades. 
Chloroquine was the antimalarial drug of choice because 
of its low cost and efficacy. The spread of chloroquine 
  resistance across malaria-endemic areas has caused an incred-
ible challenge for the majority of endemic countries.11–14 
National malaria control programs of endemic countries 
had to develop malaria treatment policies in response to 
elevated levels of drug resistance to chloroquine (CQ) 
and sulphadoxine-pyrimethamine (SP).15–19 This has led to 
an international effort to replace CQ with relatively more 
  expensive but highly effective artemisinin-based   combination 
therapies (ACTs). The drugs containing artemisinin show 
100% effectiveness after a three to five day regimen. 
  However, due to the intensive labor and length of   production, 
these drugs are costly, making them inaccessible to the 
world’s poorest countries.19
A change in international therapeutic recommendations 
does not always translate to an immediate policy change at coun-
try levels.14,20–22 According to the World Health Organization 
(WHO), all African countries have switched from using 
chloroquine, except Cape Verde and Eritrea for treatment 
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Figure 1 Chemical structure of artemisinin and derivatives. Diagram of artemisinin 
and its derivatives. 1, artemisinin; 2, artesunate; 3, artemether; 4, arteether; 5, 
dihydroartemisnin; 6, artelinic acid.
of toxicity to humans. As an antimalarial drug, artemisinin 
has a broad range of action against different stages of the 
parasite. It kills young circulating ring-stage parasites as 
well as the mature stages that sequester on blood vessels.3 
Because of these properties, artemisinin is very useful in 
cases of severe malaria. Because of its broad range of action, 
  dispensation of a single dose kills a large number of parasites. 
All the stages of the P . falciparum life cycle, including the 
gametocytes which transmit the infection to mosquitoes, 
are killed by artemisinin. Artemisinin is known to decrease 
the rate of gametocyte carriage and gametocyte density in 
a population.3–5
Although very little is known about the molecular mecha-
nism of action of artemisinin and its derivatives, there are a 
few studies that give insight into its mechanism. For instance, 
after treatment of P . berghei-infected mice and P . falciparum 
parasites grown in human erythrocytes with artemisinin, tro-
phozoites showed morphological changes, such as swelling 
and spiral deformation of the membrane of the food vacuole 
when blood samples were examined by electron microscopy.5 
Results of additional studies have shown that artemisinin is 
a blood schizontocide that has an inhibitory action on the 
parasite’s protein and nucleic acid metabolism.6 While the 
mechanism of action of artemisinin has not been elucidated, 
it was recently revealed that the endoperoxide bridge is 
essential for arteminsinin killing (Figure 1). The sarcoplasmic 
endoplasmic reticulum calcium adenosine triphosphatase 
(PfATPase 6) has been promulgated as the main target.7 
This assessment is based on mutational studies in the gene 
coding for PFATPase 6. P . falciparum parasites from French 
Guyana with point mutations in the gene encoding PfATPase 
6 showed resistance to artemisinin derivatives.8 Nevertheless, 
these findings have not been confirmed in parasites from 
other parts of the world.Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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of falciparum malaria.23 In Cape Verde, SP is used when 
chloroquine fails. Likewise, the Maldives Islands of South 
East Asia continue to use chloroquine-based antimalarial 
therapies with recourse to a combination of mefloquine 
and SP when treatment fails.23 Most malaria endemic coun-
tries have entered into partnership with the World Health 
Organization (WHO) Roll Back Malaria program since 1998 
and have thus made a concerted effort to control malaria.24,25 
The result of this effort was the enactment through National 
Malaria Control Programs with recommendation of new 
antimalarials as first-line treatments. Since 1998, new policy 
suggested that malaria endemic areas change their first-
line recommendations for the treatment of malaria at least 
twice before advocating the use of artemisinin-combination 
therapies.21,22 A good example of a country changing its poli-
cies is Tanzania. There, malaria is most commonly a disease 
of rural agricultural   communities, and widespread antima-
larial drug resistance has been   reported.12 Although a plan 
was initiated in   Tanzania, the number of cases and deaths 
due to malaria are still   increasing; this increase is thought 
to be due to resistance to antimalarial drugs. Chloroquine-
resistant falciparum malaria is widespread in Tanzania, 
and sulfadoxine-pyrimethamine (SP) was only introduced 
in 2001. Despite this, resistance to SP has been found in a 
number of areas. The first-line   treatment was changed again 
to artemisinin-based combination therapy in 2006.14
Artemisinin resistance
Artemisinin is currently playing an important role in the 
control of falciparum malaria. However, CQ and SP, used 
singly or in combination, remain the drugs of choice for the 
treatment of vivax malaria.26 Artemisinin has a very short 
half-life and quickly clears from the body by   glycoronidation, 
with CYP 2B6, the primary catalyst.27,28 This   characteristic 
renders it useless as a prophylaxis.6 However, it gave 
  credence to the hypothesis that mutations will not arise 
against artemisinin very easily. Though artemisinin and its 
derivatives were initially used as monotherapies, they are now 
used in combination because of the high rate of   emergence 
of resistance against several antimicrobial drugs given as 
monotherapies. Artemisinin is often given in   combination 
with a variety of antimalarials including those with a longer 
half-life. Indeed, artemisinin combination therapy (ACT) 
is now the suggested treatment for falciparum malaria in 
all endemic areas. In 2006, the World Health Organization 
(WHO) issued guidelines for the treatment of malaria and rec-
ommended ACT as the first-line of treatment in all endemic 
areas.3 The recommendations for global use of artemisinin 
  derivatives were founded on their outstanding tolerability, 
safety, and efficacy. With no alternative drugs, artemisinin 
was to be protected from resistance by controlled rational use 
with the development and implementation of global policies. 
During a meeting of the WHO that took place in 1998 to 
review the use of artemisinin, the experts gave advice on the 
appropriate use of artemisinin in different epidemiological 
situations.29 A report was generated outlining detailed recom-
mended drug regimens, clinical use, and priority areas for 
research.29 Drug regimens and clinical use were outlined for 
each country. A summary of the recommendations is shown 
in Table 1. Malaria endemic countries with the assistance of 
WHO have carefully developed and implemented policies 
aimed at controlling the use of artemisinin. It was recom-
mended that public health services be the sole means of 
allowing artemisinin in the market. 
Long before these efforts to prevent resistance against 
artemisinin, resistance was first reported in Pailin, Cambodia 
in the 1970s.30 This city has been the site of three successive 
waves of antimalarial resistance. Here, resistance first devel-
oped against chloroquine then sulfadoxine-pyrimethamine.3,31 
Resistant parasites have extended not only throughout 
Cambodia and Asia but also to sub-Saharan Africa, ren-
dering important weapons in the fight against falciparum 
malaria ineffective.3 Antimalarial resistance is defined as 
the increased parasite clearance time following treatment 
whereas treatment failure is defined as the presence of fever 
and parasitemia after three days of treatment. It normally 
takes three days for parasites to clear in patients after drug 
treatment.3 The first official report about the decreasing 
effectiveness of artemisinin was published by WHO in 2005.32 
In addition to four provinces in Cambodia, P . falciparum 
parasites are also believed to be resistant in two provinces 
in Thailand.31 Countries such as Cambodia, Myanmar, and 
Vietnam, which have allowed artemisinin into the market 
Table  1  Recommended  artemisinin  combination  therapies. 
Adapted  from  Roll  Back  Malaria  Partnership:  Facts  on  ACTs 
January 2006 Update
Antimalarial combinations Restrictions
Artemether/lumefantrine
Artesunate with amodiaquine In areas where the cure rate of 
amodiaquine monotherapy is greater 
than 80%
Artesunate with mefloquine Insufficient safety data to recommend 
its use in Africa
Artesunate with sulfadoxine/
pyrimethamine
In areas where the cure rate of 
sulfadoxine/pyrimethamine is 
greater than 80%Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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without the supervision of the public health services, have 
tremendous problems with resistance. In fact, artemisinin 
has been used as a monotherapy in Western Cambodia for 
nearly 30 years. In 2009, scientists confirmed the emergence 
of P. falciparum parasites that have developed resistance to 
artemisinin derivatives in Pailin, Cambodia. This resistance 
has now spread to other cities of Cambodia as well as to 
the Thai-Myanmar border. In order to combat this dilemma 
WHO has suggested that countries employ the use of ACTs, 
to lower the risk of producing more artemisinin-resistant 
Plasmodium parasites.24
Artemisinin combination therapies (ACTs) are a 
  combination of an artemisinin derivative with another 
antimalarial such as piperaqine or amodiaquine. A list of 
artemisinin-based therapies is shown in Table 1. In 2001, 
WHO launched its “Roll Back Malaria Partnership”, a cam-
paign that outlined the use of artemisinins in conjunction with 
medications such as lumefantrine, amodiaquine, mefloquine, 
sulfadoxine, or pyrimethamine.24 A list of antimalarial drugs 
and their abbreviations can be found in Table 2. As of 2006, 
56 countries in Africa, Asia, and South America adopted 
the use of WHO guidelines for treating malarial infections 
caused by Plasmodium falciparum with ACTs.24 In 2007, the 
number of countries in Africa using ACTs increased by 41. 
The impact of ACT treatment on malaria transmission may 
vary among artemisinin combinations although the effect is 
synergistic.33
Artemisinin has played a pivotal role in the control of 
malaria worldwide. The unwelcome possibility that Plasmo-
dium parasites can develop complete resistance to artemisinin 
derivatives could be a catastrophe of monumental proportion 
for global health. Currently, there are no drugs in the pipeline 
to replace artemisinin, and it could take five or more years 
to find a replacement drug.3,34 The widespread resistance of 
Plasmodium parasite to artemisinin would spell disaster for 
sub-Saharan African countries that had made significant gain 
in reducing morbidity and mortality due to malaria.
Intervention efforts spearheaded by WHO, the national 
malaria control programs, and the Gates foundation to 
contain the spread of artemisinin resistance are currently 
underway.35 The primary approach in containing the spread 
of artemisinin resistance is to control the sale of this anti-
malarial in the private sector. This involves campaigns by 
the   governmental agencies to inform the private sectors, 
which include   pharmacies and shops, about the ban against 
artemisinin monotherapy. The removal of artemisinin mono-
therapy from the market will greatly reduce the pressure 
of a single drug on the parasite and cause them to revert 
to the wild type genotypes which are genetically more fit. 
The campaigns take the form of workshops and radio and 
television broadcasts.33,35 Law enforcement agencies are also 
involved in the effort. Their role is to make sure that the ban is 
enforced. Moreover, a concerted effort to remove antimalarial 
drugs from the local stores and to allow trained villagers to 
dispense the malaria drugs after proper diagnostic tests have 
been performed is underway.33,35 This insures that every case 
of fever is not treated with antimalarials. It is possible that 
this strategy may not be successful as it is dependent on 
infected individuals displaying symptoms. In endemic areas, 
many individuals, especially adults, are asymptomatic and 
carry a low parasite load. These asymptomatic individuals 
would still able to transmit artemisinin-resistant parasites. 
To counteract this, there are programs in place in Cambodia 
to screen and treat all patients who are positive for infection 
with drugs regardless of symptoms.35 In addition, efforts 
are also aimed at prevention by intensifying the wide scale 
distribution of bednets. A population dynamic mathematical 
modeling framework was developed to explore the rela-
tive effectiveness of a variety of containment interventions 
in eliminating artemisinin-resistant malaria in western 
Cambodia.36 The most effective intervention to eliminate 
artemisinin-resistant malaria was a switch of treatment 
from artemisinin monotherapy to ACT with 4 years being 
the average estimated time for elimination of the resistant 
parasites. However, with this approach it is predicted that 
elimination of artemisinin-resistant malaria using ACT can be 
achieved only by elimination of all malaria cases in the area. 
Table 2 Abbreviations of currently used antimalarial drugs
Ae Arteether
AQ Amodiaquine
AL Artemether-lumefantrine
AM Artemether
ART Artemisinin
AS Artesunate
CL Clindamycine
CQ Chloroquine
D Doxycycline
DHA Dihydroartemisinin
MQ Mefloquine
NQ Naphroquine
PG Proguanil
PM Pyrimethamine
PPQ Piperaquine
PQ Primaquine
PYR Pyronaridine
QN Quinine
SP Sulfadoxine-pyrimethamine
T Tetracycline
TRI TrimethoprimInfection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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In this case various forms of ACT are more effective against 
infections with artemisinin-sensitive parasites, leaving the 
more   resistant infections at an increasing proportion of the 
dwindling parasite population.36,37 That in and of itself is a 
daunting task. The emergence of artemisinin in South East 
Asia and the potential spread to all malaria endemic areas 
would pose both social and economic   challenges for these 
countries.
Social impact of artemisinin 
resistance
The first change in malaria treatment in endemic areas 
involved shifting from the failing inexpensive CQ to SP, 
another inexpensive monotherapy.23,25 The spread of antima-
larial resistance with the resulting challenges of implement-
ing national malaria drug policies occurs in social contexts 
where self-medication, mistrust of government officials, and 
lack of compliance are common. The changes are introduced 
by the Ministry of Health of various governments which are 
often not trusted. In Tanzania, this took place in 2001.14 There 
was some reluctance on the part of many to use SP when 
it was first introduced to replace CQ.14,18 Because CQ was 
used for several decades and was considered to be safe and 
effective, many households in Tanzania still had stockpiles of 
CQ. Moreover, health care practitioners there had developed 
a certain attachment to CQ. To make matters worse, mothers 
of sick children felt they were being forced to abandon CQ 
which they considered to be more effective than SP because 
the recommended dose of the new drug did not quickly relieve 
fever, the outward symptom of malaria. This led to not only 
suspicion and noncompliance, but a continued use of CQ, 
the failing drug.21
Furthermore, the acceptance of new antimalarials by 
a community is dependent on the degree of knowledge 
about the new drug and its proper use. Most individuals 
are informed by health care practitioners or by materials 
displayed at health care facilities. In some cases, the media 
by way of television, and commonly radio and newspapers, 
play an important role in disseminating information about 
the new antimalarials. This can lead to fear since oftentimes 
the journalists emphasize the negative side effects of the new 
drugs. Successful transition to new antimalarials is strongly 
dependent on journalists being educated about the new drug 
in order to disseminate correct information to the general 
public. Once a negative opinion is formed about a drug, the 
general public develops a prejudice against it and it is a major 
challenge to accept the new antimalarial despite its effective-
ness. It has been reported that mothers would not give the   
new antimalarials because of their perceived ill effects.18,21 
They would go as far as inducing vomiting in their children 
to prevent them from consuming the new drug. This puts 
increased pressure on health care workers who have to closely 
monitor patients to ensure   ingestion of the drug before being 
allowed to return to their home. In addition, changes to new 
drugs are always accompanied by anxieties on the part of the 
public regarding perceived or experienced adverse reactions. 
Although few individuals had experienced adverse reactions, 
every person interviewed had learned through the media 
about deaths following the use of SP.21
When SP started to fail in 2003, introduction of   artemisinin 
combination therapies (ACTs) was met with even greater 
resistance by members of the community, especially caregiv-
ers, because ACTs were not made available over the counter 
like chloroquine.18,21 It is very likely that similar reactions 
would be observed if a new regimen of antimalarials were to be 
recommended so soon after switching to ACT. It was expected 
that ACT would have a lifespan as long as chloroquine. The 
rise and spread of acquired resistance to artemisinin-based 
therapy might erode the trust of the population in the ability 
to provide a long-lasting drug against malaria. There were 
already thoughts of government conspiracy aimed at killing 
off the population or experimenting on the population with 
new antimalarials from some participants in a focus discus-
sion group aimed at assessing the perception of various social 
groups in Tanzania about the recommendation of SP as the 
new first-line of treatment against malaria.21
Economic impact of malaria
In our consideration of the economic impact of artemisinin 
resistant malaria, we first consider the impact of malaria itself 
on a country’s economy. We will then consider the impact 
from the use of artemisinin. Lastly, we consider the economic 
impact of artemisinin-resistant malaria.38
First, we acknowledge that there are many factors that 
have an impact on a country’s economy other than malaria. 
Some of these factors that result in low incomes and low 
economic growth are poor soils, low agricultural produc-
tivity, tropical diseases other than malaria, trade barriers, 
weak institutions, poor economic policies, ethnic conflict, 
and the residue of colonization.38 Although all these factors 
play a role in the economy of a country there are reports that 
  consider the economic impact of malaria to be so high that 
it is considered the major cause of poverty.39
The economic impact of malaria takes a toll on the 
  population living in an endemic area. It is actualized in 
  individual as well as government costs. To an individual, the Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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cost can accumulate in the expense of medical   treatment, 
travel to dispensaries and clinics, preventions, and burial 
upon death, as well as loss of income from days away from 
work and school. Malaria has even been implicated in learn-
ing disability in children by which the far reaching effects 
cannot be realized and calculated in the effect of malaria 
on an economy.39 On the other hand, governments sustain 
costs in health care facility maintenance, drugs and sup-
plies, insecticide spraying, and bednet distributions. They 
also sustain loss of income from sick workers, economic 
ventures, and lack of tourism. For example, peak periods 
of malaria transmission often coincide with the peak period 
of agricultural activity.39 Farmers prefer to plant subsistent 
crops rather than more labor intensive cash crops.24 These 
costs impede economic growth in malaria endemic coun-
tries. It is estimated that the economy of malaria endemic 
countries is 1.3% lower than countries without malaria. 
This estimate seems low. However, when it is taken into 
consideration that most malaria endemic (GDP) countries 
are developing with lower gross domestic product, defined 
as the market value of all final goods and services made 
within the borders of a country in a year, it is a major factor 
for endemic countries.40
The GDP of a country is often positively correlated with 
the standard of living. The standard of living of persons 
living in a malaria endemic area can remain low because of 
malaria. Malaria disproportionately affects poor people who 
cannot afford treatment or have limited access to health care. 
These factors trap families and communities in a downward 
spiral of poverty.20 The economic gap in prosperity between 
countries with and without malaria grows every year.24 It is 
interesting to note that in almost all countries that have eradi-
cated malaria, there was an immediate economic growth that 
was faster than neighboring countries. These examples stem 
from data collected from southern European countries such 
as Greece, Italy, and Spain.40 The richest countries in Africa 
are free of malaria and located in the northern and southern 
extremes of the continent. The gross domestic product of 
malarial countries in 1995 was $1,526 compared to $8,268 
in countries without malaria.40
The economic impact of the use  
of artemisinin
The era of cheap effective antimalarials has ended but pov-
erty has not. The cost of artemisinin combinational therapies 
is more than any other antimalarial monotherapy or non-
artemisinin combinational therapy. In Tanzania $2.14 is spent 
on malaria control per person per year. This is a huge debt 
on the country’s economy. This number represents 39% of 
the health cost and 1.1% of the country’s GDP. 39 However, 
in the long run, treating sick people so that they can return 
to work and school will help the economy. This will translate 
to economic growth and poverty reduction. In Cameroon, 
the government subsidizing malarial combination treatment 
made drug therapy affordable for all people.41 This greatly 
relieved both individuals and the government from the burden 
of malaria. Overall, this will result in economic development 
because workers can gain income and economic ventures and 
tourism will start to flourish.
The economic impact  
of artemisinin resistance
As with any antimalarial drug resistance, artemisinin 
drug resistance has a major impact on health services. 
With the increase of transmission and drug failures, 
medical care needs increase. There is a demand for more 
patient care, diagnostic procedures, and increased costs 
associated with combination treatments.38 So the cycle 
continues as if the drug never existed. In some countries, 
chloroquine is still being used even with high failure 
when alternative drugs such as SP are available. This is a 
health policy failure, however, policy changes have been 
significantly associated in terms of cost with retraining 
health care workers, printing new drug regimens, and 
stocking new drugs.42
Another cost of artemisinin resistance is the increase in 
morbidity and mortality in the tropical world.43 It is esti-
mated that the number of malarial deaths would double with 
the spread of artemisinin-resistant parasites. People suffer 
and die because they will not be able to treat them. The 
economic toll would topple the economy of any develop-
ing country providing health care to a great portion of the 
population of workers and students with no tax revenue in 
return. The economic prosperity of Thailand and Vietnam, 
the epicenter of drug resistance to other antimalarials, is 
threatened by the looming threat of artemisinin resistance. 
Dr Pascal Ringwald of WHO, who spoke at the ASTMH 
session in November of 2009 said: “The loss of artemisinin 
derivatives to resistance could have a devastating effect on 
health in tropical countries, and would threaten current 
global efforts to eliminate malaria, as there are very few 
innovative replacement therapies in the pipeline at the late 
stage of development”. The cost in human morbidity and 
mortality across the globe would be detrimental to eco-
nomic development and could reverse any progress that 
antimalarial efforts have made.44 Although the outlook is Infection and Drug Resistance 2010:3 submit your manuscript | www.dovepress.com
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bleak, we are hopeful that some new drug or vaccine will 
come with billions of dollars put forth in the research effort. 
It is a matter of a race against time.
Future considerations
Looking forward, a multipronged approach against 
malaria, a formidable scourge to worldwide health, can be 
put in place. Given that artemisinin combination therapies 
are more expensive than current drugs, several strate-
gies can be undertaken to prevent further emergence of 
resistance against this valuable antimalarial. First, some 
countries could switch to SP as an interim measure. This 
would delay the higher treatment cost of ACTs. How-
ever, SP resistance is expected to rise within a few years 
leading to increased morbidity and mortality.42 Second, 
another source of artemisinin is from partial chemical 
synthesis. This will help ensure that ACT manufacturers 
have a consistent, reliable, high quality, and inexpen-
sive supply of the compound. This idea was put forth 
by the US agency for International Development which 
commissioned the Institute of Medicine (IOM) in 2001 
to ensure broad access to effective antimalarials. The 
IOM recommended a global subsidy program of ACTs 
treatment. Therefore, expensive ACTs (cost $2 USD per 
treatment) would cost 10 cents per treatment as did CQ 
and SP. Furthermore, only those patients with a proven 
case of falciparum malaria would receive ACTs.45 Another 
intervention comes from local and international compa-
nies doing business in endemic areas. They are learning 
to support malaria control thus reducing absenteeism 
and losses in productivity.24 Finally, the continued use of 
insecticide-treated bednets, and residual spraying should 
effectively control malaria and slow the spread of drug 
resistance. Although this multipronged approach maybe 
effective, they must be implemented and they also must 
be acceptable to the patients and health care workers. 
Moreover, patients must adhere to treatment. Some 
social interventions may be needed to increase successful 
malaria control.
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